Device Trial Radar · NCT07689812
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
920
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Aug 2034
Study completion May 2036
Sponsor
- Lead sponsor
- Natera, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI therapy in patients with histologically confirmed advanced/metastatic non-small cell lung cancer (NSCLC), melanoma, microsatellite instability-high (MSI-High)/Deficient Mismatch Repair (dMMR) colorectal cancer (CRC), renal cell carcinoma (RCC) and other solid tumors. This study will be conducted in approximately to 100 sites.
Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- NSCLC (Non-small Cell Lung Cancer)
- NSCLC (Non-small Cell Lung Carcinoma)
- NSCLC
- Melanoma (Skin Cancer)
- Melanoma (Skin) Stage IV
- CRC
- MSI High Colorectal Cancer
- DMMR Colorectal Cancer
- RCC, Renal Cell Cancer
- RCC
- Solid Tumors
- Metastatic Solid Tumors
- Advanced Solid Tumors
- Advanced Solid Tumors Cancer
Interventions
Signatera Genome ultra-sensitive ctDNA blood testDevice
The test is used to monitor for disease recurrence.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate that ctDNA-guided intermittent ICI therapy results in at least 50% of patients who do not reinitiate systemic therapy prior to 6 months from randomization.Time frame: 6 months from randomization
- To demonstrate that ctDNA-guided intermittent ICI therapy is non-inferior to SoC continuous ICI therapy as measured by 36 month OS in advanced/metastatic solid tumor patients.Time frame: 3 years from randomization to death from any cause
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.